医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Biological E and GVK BIO Announce Strategic R&D Partnership

2019年07月31日 PM08:00
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

GVK BIO, a leading global Contract Research and Development Organisation (CRDO), and BE Pharmaceuticals Inc (BE Inc), a rapidly growing pharmaceutical company that develops, manufactures and markets complex and critical injectable products, announced a strategic collaboration in drug product development.

As part of the partnership, GVK BIO will develop certain set of injectable products for BE Inc. Development work will include Pre-Formulation studies, Formulation Development, Analytical Method Development and Technology Transfer to a BE facility. The goal of the collaboration will be the successful regulatory submissions and marketing authorizations for the products in the US, Europe and RoW markets.

“GVK BIO’s Formulations Development team has the technical expertise and track record to deliver on projects, and we look forward to working with the BE team to accelerate product development timelines and reduce cost to market,” said Manni Kantipudi, Director & Chief Executive Officer, GVK BIO.

“We are excited to work with GVK BIO, an established CRDO,” said Narender Mantena, CEO, Speciality Generic Injectable, BE Pharmaceuticals. “This collaboration will support BE in building a robust pipeline, especially for critical injectable products.”

About GVK BIO

GVK BIO, a Contract Research & Development Organization that services the global Pharmaceutical industry is headquartered in Hyderabad, India and has five sites across the globe. Established in 2001, GVK BIO serves large and small pharma clients across the R&D value chain with a focus on speed and quality, ensuring safety and compliance. GVK BIO’s team of over 2200 scientists, are supported by a no-conflict business model, modern facilities, strong customer-centric culture, and focus on bringing their customers’ products to market rapidly and cost effectively. www.gvkbio.com

About Biological E. Limited

Biological E. Limited (BE) is a privately held company established in 1953. BE is a globally focused biopharmaceutical company, which develops, manufactures and markets innovative vaccines and biologics that respond to healthcare needs worldwide. The company’s product development efforts are driven by an internationally experienced management team and the company has several strategic partnerships with leading biotechnology and pharmaceutical companies and research institutes around the world.

BE Pharmaceuticals Inc is a subsidiary of Biological E. Limited and focuses on Speciality Generic Injectables. www.biologicale.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20190731005071/en/

CONTACT

Dorothy Paul

Dorothy.paul@gvkbio.com

Phone: +91 9908130236

K. Vijay Amruth Raj

Vijay.Kammari@biologicale.com

Phone: +91 8374077433

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Seoul Viosys’ Violeds Modules Proven to Disinfect 99% of Airborne Viruses in a Recent Testing Result
  • Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
  • Kaye推出适用于冷链运输市场的Kaye® Log -80℃ 疫苗温度记录器,以满足COVID-19疫苗储存和运输的要求
  • Kaye® (ケイ)は、COVID-19ワクチンの輸送・保管のニーズに応えるためにKaye® ログ -80ワクチン温度ロガーを、コールドチェーン市場向けに導入(発売)します。
  • DNP的新型非接触式透明屏幕可通过手的动作进行操作